Showing results (61-70 of 1,083) with videos related to
Sort By:
Pageof 109
Therapeutic Advances in Cardiovascular Disease|December 12, 2019
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical useDavide Capodanno, Rocco P Milluzzo, Dominick J AngiolilloFuture Cardiology|February 3, 2021
Canakinumab for secondary prevention of coronary artery diseaseLuis Ortega-Paz, Davide Capodanno, Dominick J AngiolilloExpert Review of Cardiovascular Therapy|July 31, 2010
Update on the clinical development of cangrelorMasafumi Ueno, José Luis Ferreiro, Dominick J AngiolilloExpert Review of Cardiovascular Therapy|July 1, 2011
Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitusDominick J Angiolillo, Marco Roffi, Antonio Fernandez-OrtizExpert Review of Cardiovascular Therapy|April 22, 2009
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary interventionPiera Capranzano, Jose Luis Ferreiro, Dominick J AngiolilloExpert Review of Cardiovascular Therapy|October 10, 2009
Cangrelor: a review on its mechanism of action and clinical developmentJosé Luis Ferreiro, Masafumi Ueno, Dominick J AngiolilloEuropean Heart Journal|September 7, 2011
Current concepts on coronary revascularization in diabetic patientsMarco Roffi, Dominick J Angiolillo, A Pieter KappeteinFuture Cardiology|June 2, 2011
Antiplatelet drug therapy: role of pharmacodynamic and genetic testingAntonio Tello-Montoliu, Masafumi Ueno, Dominick J AngiolilloExpert Opinion on Investigational Drugs|October 29, 2010
Inhibiting PAR-1 in the prevention and treatment of atherothrombotic eventsSalvatore Davide Tomasello, Dominick J Angiolillo, Shinya GotoJournal of Cardiovascular Development and Disease|October 26, 2022
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary InterventionXuan Zhou, Dominick J Angiolillo, Luis Ortega-PazPageof 109